> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 5 Pharmas Settle Improper Reimbursement Case
- URL: https://www.fdaweb.com/5-pharmas-settle-improper-reimbursement-case/
- Published: 2023-08-09T12:00:00.000Z
- Updated: 2026-09-14T18:49:11.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155063

Shire, Baxter International, Baxalta, Viropharma and Takeda Pharmaceuticals have agreed to pay $42 million to settle an enforcement action brought under the Texas Medicaid Fraud Prevention Act (TMFPA) involving allegedly improper reimbursements for certain pharmaceuticals. The alleged violations were first brought in a lawsuit filed by a whistleblower under the *qui tam* provisions of the TMFPA.

“The settlement resolves allegations that the drug manufacturers violated the TMFPA by providing, directly or indirectly, nursing and reimbursement services to Texas Medicaid providers for certain pharmaceutical drugs, as well as by paying clinical nurse educators to refer or recommend the drug Vyvanse to providers from January 2014 to December 2015,” a [release](https://www.texasattorneygeneral.gov/news/releases/office-attorney-generals-civil-medicaid-fraud-division-recovers-427-million-taxpayer-funds?ref=fdaweb.com) from Texas attorney general **Ken Paxton** says.